Oncology Innovations: Novel Approaches to Immunotherapy in mESCCAn interactive infographic to educate clinicians on advances in the therapeutic paradigm for patients with esophageal carcinoma.CME: 0.5
Promoting Recognition, Diagnosis, and Treatment of Cold Agglutinin DiseaseDescribe the pathogenesis of cold agglutinin disease (CAD), the mechanism of disease, its symptoms, and its possible consequencesCME: 1.0
Keeping an Eye Out: Emerging Trends in the Management of Metastatic Uveal MelanomaOutline how new or emerging options may fit into existing treatment algorithms for patients with uveal melanoma. CME: 0.75
Efficacy of Targeted Therapy in Genetic Subtypes of Aggressive Lymphoma – Module 3This activity provides an overview of molecular and clinical subtypes of lymphoma and the mechanisms by which targeted therapies work for molecular subtypes. CME: 1.0
Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors: Emerging Combinations for Newly Diagnosed CLL High-Risk Relapsed/Refractory (R/R) CLLReview patient-specific criteria that determine eligibility for first-line and subsequent CLL therapies CME: 1.5
Burst Expert Illustrations and Commentaries™: Visualizing Gene Therapy Approaches in Hemophilia AAssess the severity of hemophilia A according to clinical presentation and results of factor assays CME: 0.25
Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTPReview diagnostic challenges that are specific to acquired, immune-mediated TTP (thrombotic thrombocytopenic purpura ) CME: 0.75
Optimizing Outcomes in Cold Agglutinin Disease: Exploring the Impact of Rapid Diagnosis and Emerging Therapeutic AgentsDescribe the clinical burden of cold agglutinin diseaseCME: 1.0